AstraZeneca has made a significant deal with the White House aimed at lowering drug prices in the U.S., becoming the second pharmaceutical company to do so under the Trump administration. This agreement is part of a broader initiative to make medications more affordable for Americans, which is crucial given the rising healthcare costs. Such collaborations between drugmakers and the government could lead to more accessible treatments for patients, highlighting the importance of addressing drug pricing in the healthcare system.